Overview

A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.
Phase:
Phase 4
Details
Lead Sponsor:
Takeda
Treatments:
Alogliptin
Pioglitazone